Startups
Elanix Biotechnologies develops and commercializes tissue regeneration products for chronic and acute wound care, and advanced skin care products for dermatological and gynaecological applications.
Our technology is the result of 30 years of progenitor cell research and development by Prof. Lee Ann Laurent-Applegate and her team at the University Hospital of Lausanne (CHUV).
The Company is headquartered in Berlin, Germany with offices in Nyon, Switzerland and Wiesbaden, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.
Our technology is the result of 30 years of progenitor cell research and development by Prof. Lee Ann Laurent-Applegate and her team at the University Hospital of Lausanne (CHUV).
The Company is headquartered in Berlin, Germany with offices in Nyon, Switzerland and Wiesbaden, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.
Overview
Location
Switzerland, Grisons, Castaneda
Employees
11-50
Founded date
2013
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 3, 2017 | Elanix ramps up commercialisation and marketing | |
| Apr 19, 2017 | 15 Swiss startups to present at Swiss Biotech Day | |
| Feb 27, 2017 | Elanix Biotechnologies raises CHF5 million | |
| Sep 5, 2016 | Elanix Biotechnologies AG raises EUR 1.5 million in two financing rounds |